کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5586977 | 1568716 | 2017 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ATATNF antagonistBath Ankylosing Spondylitis Disease Activity IndexspondyloarthritisDAS28DMARDsSPANHSECLPSApsoriatic arthritis - آرتریت پسوریاتیکRheumatoid arthritis - آرتریتروماتوئیدNeutralizing antibodies - آنتی بادیهای ناتریالAnkylosing spondylitis - اسپوندیلیت انکیلوزانElectrochemiluminescence assay - الکتروشیمیومومسانسانس آزمایشElectrochemiluminescence - الکتروکمی لومینسانسImmunogenicity - ایمنی زاییBASDAI - بسطامیLOD یا Limit of detection - حد تشخیصdisease-modifying antirheumatic drugs - داروهای ضد رماتیسمی اصلاح کننده بیماریRheumatoid factors - عوامل روماتوئیدlimit of detection - محدودیت تشخیصDisease activity score 28 - نمره فعالیت بیماری 28Positive control - کنترل مثبت
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
علوم غدد
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS). Use of an electrochemiluminescence platform permitted development of fit-for-purpose immunoassays. Serum samples from patients, taken prior to and at 12 and 24Â weeks of treatment, were retrospectively analysed for levels of adalimumab and ATA. Overall, the antibody prevalence was 43.6% at 12Â weeks and 41% at 24Â weeks of treatment. Disruption of immune complexes by acid dissociation, a strategy often adopted for this purpose, only marginally increased the antibody prevalence to 48.7% and 46% at 12 and 24Â weeks respectively. We found that antibody formation was associated with decreasing levels of circulating adalimumab, but no direct effect on disease activity was evident as assessed using DAS28 for RA patients and BASDAI for PsA and AS patients. However, a negative correlation of free adalimumab trough levels with disease activity scores was observed. Data showed that adalimumab levels can serve as an indicator of ATA development which can then be confirmed by ATA testing. Monitoring of both therapeutic and antibodies should be considered during adalimumab therapy to allow clinicians to personalise treatments for maximal therapeutic outcomes.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cytokine - Volume 96, August 2017, Pages 16-23
Journal: Cytokine - Volume 96, August 2017, Pages 16-23
نویسندگان
Isabelle Cludts, Francesca Romana Spinelli, Francesca Morello, Jason Hockley, Guido Valesini, Meenu Wadhwa,